Andrea Ilari’s research focuses on structure-based drug design and the structural and functional characterization of therapeutic targets. In particular, he have investigated Trypanothione Reductase as a target for the development of novel antileishmanial drugs, combining X-ray crystallography with medicinal chemistry approaches. In parallel, I have studied the Sigma-1 Receptor (S1R) and its role in neuroprotection, identifying and characterizing S1R agonists with potential therapeutic applications in neurodegenerative diseases, including Huntington’s disease.
